The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods

Barbara Zdrazil,Eloy Felix,Fiona Hunter,Emma J. Manners, James Blackshaw, Sybilla Corbett,Marleen de Veij,Harris Ioannidis, David Mendez Lopez, Juan F. Mosquera,Maria Paula Magarinos,Nicolas Bosc,Ricardo Arcila,Tevfik Kiziloren,Anna Gaulton,A. Patricia Bento, Melissa F. Adasme, Peter Monecke, Gregory A. Landrum,Andrew R. Leach

NUCLEIC ACIDS RESEARCH(2023)

引用 1|浏览8
暂无评分
摘要
ChEMBL (https://www.ebi.ac.uk/chembl/) is a manually curated, high-quality, large-scale, open, FAIR and Global Core Biodata Resource of bioactive molecules with drug-like properties, previously described in the 2012, 2014, 2017 and 2019 Nucleic Acids Research Database Issues. Since its introduction in 2009, ChEMBL's content has changed dramatically in size and diversity of data types. Through incorporation of multiple new datasets from depositors since the 2019 update, ChEMBL now contains slightly more bioactivity data from deposited data vs data extracted from literature. In collaboration with the EUbOPEN consortium, chemical probe data is now regularly deposited into ChEMBL. Release 27 made curated data available for compounds screened for potential anti-SARS-CoV-2 activity from several large-scale drug repurposing screens. In addition, new patent bioactivity data have been added to the latest ChEMBL releases, and various new features have been incorporated, including a Natural Product likeness score, updated flags for Natural Products, a new flag for Chemical Probes, and the initial annotation of the action type for similar to 270 000 bioactivity measurements. Graphical Abstract
更多
查看译文
关键词
drug discovery platform,chembl database,multiple bioactivity database types
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要